Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Elinzanetant in Japanese Women
NCT04981431Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of elinzanetant in vasomotor symptoms (6 arms), sponsored by Bayer. Primary endpoint: Treatment-Emergent Adverse Events. Started Aug 2021; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04981431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981431.